ArticleLipids in health and disease2025

Effects of residual inflammatory and cholesterol risks on cardiovascular events with evolocumab in patients with acute coronary syndrome undergoing percutaneous coronary intervention.

Yahao Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.